3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
4
Thoracic
3
Sarcoma
3
Gastrointestinal
3
Endocrine
3
NET
2
Gynecologic
2
Genitourinary
2
Dermatologic
2
CNS
2
Breast
2
Other solid neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
35
Neoplasm Metastasis
7
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Triple Negative Breast Neoplasms
4
Thyroid Neoplasms
4
Thyroid Cancer, Papillary
3
Sarcoma
3
Pancreatic Neoplasms
3
Neoplasms by Site
3
Melanoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thyroid Diseases
2
Thoracic Neoplasms
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Lung Diseases
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Endocrine System Diseases
2
Interventions
larotrectinib
1
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Salivary Gland Neoplasms
×
Breast
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA